by John C. Byrd, MD; Ian W. Flinn, MD, PhD; and Jeff Sharman, MD
Chronic lymphocytic leukemia (CLL) treatment can impact quality of life (QOL) in many different ways. Psychological aspects of treatment may be imp......READ MORE
by John C. Byrd, MD; Ian W. Flinn, MD, PhD; and Jeff Sharman, MD
Our featured experts describe the latest data that guide decisions on initial therapy for the treatment of chronic lymphocytic leukemia (CLL). Incr......READ MORE
by John C. Byrd, MD; Ian W. Flinn, MD, PhD; and Jeff Sharman, MD
Our featured experts have seen a remarkable transformation in the treatment of chronic lymphocytic leukemia (CLL) in the span of their careers. Adv......READ MORE
by John C. Byrd, MD; Ian W. Flinn, MD, PhD; and Jeff Sharman, MD
Chronic lymphocytic leukemia (CLL) with TP53 aberrancy represents a high-risk subset for which optimal therapy has yet to be defined. Combination t......READ MORE
by John C. Byrd, MD; Ian W. Flinn, MD, PhD; and Jeff Sharman, MD
Targeted agents have dramatically improved clinical outcomes in patients with chronic lymphocytic leukemia (CLL) over the last decade. Nonetheless,......READ MORE
